IMbrave150: Efficacy and Safety of Atezolizumab Plus Bevacizumab vs Sorafenib in Patients With Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma—An Exploratory Analysis of the Phase III Study
Introduction: The Phase III IMbrave150 study established atezolizumab + bevacizumab as standard of care in patients with unresectable hepatocellular carcinoma (HCC). This exploratory analysis reports efficacy and safety results in patients with baseline Barcelona Clinic Liver Cancer (BCLC) Stage B d...
Salvato in:
| Autori principali: | , , , , , , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Karger Publishers
2022-11-01
|
| Serie: | Liver Cancer |
| Accesso online: | https://www.karger.com/Article/FullText/528272 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|